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Abstract
Purpose of the Review Identification of loci and common single-nucleotide polymorphisms (SNPs) that have modest effects on
plasma lipids have been used to confirm or refute the causal role of lipid traits in the development of coronary heart disease
(CHD), and as tools to identify individuals with polygenic hypercholesterolemia.
Recent Findings Several groups have reported on the use of SNP scores in distinguishing individuals with a clinical diagnosis of
familial hypercholesterolemia (FH) with a monogenic or polygenic etiology. We review evidence that those with monogenic FH
have worse prognosis and discuss the possible mechanisms for this and their management.
Summary Individuals with a clinical phenotype of FH and a monogenic cause are at greater risk of CHD than those where no
causative mutation can be found. The patients with polygenic hypercholesterolemia would not require elaborate cascade screen-
ing or secondary care input for their management.
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Introduction
The causal relationship between low-density lipoprotein cho-
lesterol (LDL-C) and coronary atherosclerosis has been
shown in several previous studies [1••]. Multiple randomized
trials have demonstrated that lowering LDL-C by treatment
with a statin reduces the risk of major coronary events [2].
In people with similar total cholesterol levels, different
rates of coronary heart disease (CHD) events have been
reported. It is well established that diet, physical inactiv-
ity, smoking, elevated blood pressure, diabetes, obesity,
and thrombogenic factors play important roles in increas-
ing risk of CHD. The contribution of these modifiable risk
factors to developing a future coronary event is consider-
able, particularly in combination with non-modifiable per-
sonal characteristics such as age, male gender, and family
history of early-onset CHD [3]. Results from a 12-year
follow-up of 316,099 men screened for the multiple risk
factor intervention trial (MRFIT) showed a strong graded
relationship between serum cholesterol levels and CHD
mortality [4].
Different factors are known to increase LDL-C concentra-
tion. The secondary causes such as diabetes mellitus, hypo-
thyroidism, obesity, nephrotic syndrome, and excess alcohol
intake are well-known. Among the hereditary causes, it is
important to differentiate between monogenic and polygenic
hypercholesterolemia as this might affect the patient’s man-
agement in long-term.
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Polygenic Hypercholesterolemia
Polygenic hypercholesterolemia is a common cause of elevat-
ed serum cholesterol concentrations. It represents the cases
with a raised LDL-C with serum triglyceride concentrations
within the reference range. Some patients with mixed
dyslipidemias (elevations of both LDL-C and triglycerides)
may also have polygenic hypercholesterolemia along with
another condition such as metabolic syndrome or obesity.
Polygenic hypercholesterolemia is sometimes difficult to
be differentiated clinically from familial hypercholesterolemia
(FH). The presence of a mutation in any one of three common
genes is responsible for causing FH. Most commonly, a mu-
tation is found in the LDLR gene encoding the LDL receptor,
or in the APOB gene encoding for apolipoprotein B, which is
the major protein of the LDL particle, and a single mutation
p.Arg3527Gln is found in about 5% of clinical FH patients in
the UK. Finally, and least frequently, FH can be caused by a
gain-of-function mutation in the PCSK9 gene (proprotein
convertase subtilisin kexin 9), encoding the PCSK9 protein
responsible for degradation of the LDL receptor during its
intracellular recycling. FH is diagnosed either on phenotypic
criteria, involving an elevated LDL-C level plus a family his-
tory of elevated LDL-C, premature CHD, or with a genetic
testing [5]. However, a mutation in the above genes can only
be identified in about 40–60% of people with clinically
suspected FH [6], raising the question of what is the genetic
etiology in the remainder.
Although some patients with no detected mutation may
have a mutation in a yet-to-be identified gene, in the majority
of this group, we now believe that there is a polygenic expla-
nation. The Global Lipid Genetic Consortium (GLGC) meta-
analysis of genome-wide association study identified 95 loci
where common variants affect LDL-C level [7]. These loci
contribute not only to normal variation in lipid traits but also
to extreme lipid phenotypes. Talmud et al. showed that an
accumulation of common small-effect LDL-C-raising alleles
could increase the LDL-C level as high as the level in mono-
genic FH patients and cause polygenic hypercholesterolemia
[6]. The 12 single-nucleotide polymorphisms (SNPs) used in
this score are shown in Table 1. A “weighted” score improved
accuracy, and was created bymultiplying carriage of the LDL-
C raising allele of the SNPs by the GLGC weight. Futema
et al. found that addition of 21 LDL-C-raising SNPs did not
significantly improve the ability of the SNP score to discrim-
inate between polygenic hypercholesterolemia and healthy
subjects and a weighted score of six SNPs performed as well
as the 12-SNP score. Using this approach, this study con-
firmed the lower SNP score in samples of patients with no-
mutation from six European countries, demonstrating the ro-
bustness of the tool [9, 10].
We estimated that in more than 80% of those with a clinical
diagnosis of autosomal dominant FH but with no detectable
mutation in LDLR/APOB/PCSK9, the polygenic explanation
is most likely cause of their hypercholesterolemia [10]. In the
remainder, a mutation in a novel gene may be present [6]. In
an audit of the genetic testing that incorporated 12 LDL-C-
raising SNPs associated with LDL-C concentrations above the
diagnostic threshold for FH, it was found that approximately
36% of the cases had an FH-causing mutation and among the
patients where no mutation was found, 54% had a SNP score
consistent with an increased likelihood of a polygenic hyper-
cholesterolemia [11].
Talmud et al. proposed that only those with a monogenic
cause for their phenotype be given the diagnosis of FH, and
the remainder be termed “Polygenic Hypercholesterolemia”
[6]. In the polygenic group, cascade testing will be less cost-
effective, since only about 30% of relatives will have elevated
LDL-C compared to the 50% seen in monogenic families
[12]. Clearly, those with a polygenic cause of their hypercho-
lesterolemia will need and benefit from lipid lowering therapy,
but the question remains as to whether their future CHD risk is
as great as those with monogenic FH.
Factors that complicate clinical diagnostic accuracy of
monogenic and polygenic hypercholesterolemia is the pres-
ence of multiple genes that have a small positive effect on
LDL-C concentration, raising levels to those consistent with
FH, or the presence of compensatory genes that lower LDL-C
below thresholds for FH diagnosis. As an example of this, the
Arg46Leu variant in PCSK9 is a loss of function variant that is
associated with ~ 12% lower LDL-C levels in subjects in the
general population but with ~ 28% lower CHD risk [13]. This
confirms the LDL-C burden hypothesis (see later), where life-
long low LDL-C is associated with a significant reduction in
CHD risk.
Atherosclerosis
The number of studies carried out to evaluate the severity of
the atherosclerosis in polygenic hypercholesterolemia is very
limited. Many papers report that the prevalence of CHD is
higher in FH patients where a mutation was found compared
to those with a clinical diagnosis of FH where no mutation can
be found. Support for this also comes from the UK Simon
Broome register where patients with a clinical diagnosis of
definite FH had a 35% higher standardized mortality ratio
(SMR) for CHD than those with a clinical diagnosis of possi-
ble FH (SMR 2.4 vs. 1.78) [14]. We know that up to 80% of
those with clinical diagnosis of definite FH will carry an FH-
causing mutation while by contrast, a mutation is detected in
only 25–30% of possible FH patients. This means that at least
80% are likely to have a polygenic cause of their FH pheno-
type, and therefore the much lower death rate fromCHD in the
possible FH patients supports the view that the amount of
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coronary atherosclerosis in polygenic hypercholesterolemia
will be less.
The higher CHD risk in FH subjects with a monogenic
detected mutation has been recently shown in a study for
the USA [15••]. Using next-generation sequencing (NGS)
for the known FH genes among 20,485 CHD-free individ-
uals, 1386 (6.7%) had LDL-C > 4.9 mmol/l (189 mg/L),
and of these, 24 (1.7%) carried a known FH mutation. As
expected, in the no-mutation group, increasing levels of
LDL-C were associated with higher risk of CHD, with
individuals with LDL-C > 4.9 mmol/l (189 mg/L) having
a sixfold higher risk for CHD than those with LDL-C <
3.7 mmol/l (144 mg/dL). However, over the entire spec-
trum of LDL-C, those with an identified FH-causing mu-
tation had 2–3-fold-elevated CHD risk compared to those
with the same LDL-C but with no identified mutation
(i.e., a polygenic plus environmental cause of their elevat-
ed lipid level).
Finally, we have recently demonstrated that in polygen-
ic patients who had an LDL-C level as high as the mono-
genic FH, carotid intima media thickening (cIMT) and
coronary calcification were lower than the monogenic
FH patients [16•]. We compared the severity of carotid
and coronary subclinical atherosclerosis between these
two groups who had no previous evidence of cardiovas-
cular disease. All individuals were treated with lipid-
lowering therapy and no differences were seen in on-
treatment lipid levels, as well as in other conventional
atherosclerosis risk factors between groups. As shown in
Table 2, after adjustment for age and gender, the means of
cIMT measurements were significantly higher in several
regions of the carotid tree in monogenic FH patients. In
addition, coronary artery calcification (CAC) were signif-
icantly greater in 124 monogenic than 42 polygenic pa-
tients recruited form hospitals in the UK and Holland,
with a greater prevalence of individuals with CAC > 100
(associated with elevated cardiovascular risk), observed in
those with monogenic FH. Therefore, while CHD risk is
high in polygenic hypercholesterolemia compared to the
general population, the severity of the disease might not
be the same as the monogenic FH.
Why Is the Onset of CHD Earlier in Monogenic
vs. Polygenic Hypercholesterolemia?
Premature CHD is an established phenomenon of FH,
with the average age of onset of coronary symptoms
shown to be significantly lower in men than women, with
a mean age of 45 years compared to 55 years for women
[17]. The risk and age of onset of atherosclerosis in peo-
ple with monogenic FH tends to be proportional to the
extent and duration of raised LDL-C, calculated as a
cholesterol-year score [18]. This might be explained by
Table 1 Global Lipid Genetic
Consortium 12 SNP LDL-C gene
score, showing the LDL-C-
raising allele
CHR SNP Gene Minor* Common* GLGC Weight for Score MAF WHII
1 rs2479409 PCSK9 G A 0.052 0.35
1 rs629301 CELSR2 G T 0.15 0.21
2 rs1367117 APOB A G 0.10 0.33
2 rs4299376 ABCG8 G T 0.071 0.32
6 rs1564348 SLC22A1 C T 0.014 0.17
6 rs1800562 HFE A G 0.057 0.07
6 rs3757354 MYLIP T C 0.037 0.21
11 rs11220462 ST3GAL4 A G 0.050 0.13
14 rs8017377 KIAA1305 A G 0.029 0.48
19 rs6511720 LDL-R T G 0.18 0.13
19 rs429358 APOEψ C T 0.15
19 rs7412 APOEψ T C 0.08
19 ε2ε2 APOE − 0.9
19 ε2ε3 APOE − 0.4
19 ε2ε4 APOE 0.2
19 ε3ε3 APOE 0
19 ε3ε4 APOE 0.1
19 ε4ε4 APOE 0.2
* Risk alleles (LDL-C-raising) are indicated in bold. MAF, minor allele frequency. WHII is a UK-based study of
healthy Caucasian subjects (n = 3020)
ψAPOE weights were based on haplotypic effects taken from [8]. Genes shown in bold are those where rare
mutations of large effect on function cause FH
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the fact that the monogenic FH patients have had a raised
cholesterol level since birth. The Simon Broome DNA
study, where 410 definite FH patients were examined,
showed that compared to those without an FH-causing
mutation, in those with a mutation, the odds ratio for
having CHD was 1.84 [19]. In patients with polygenic
hypercholesterolemia, while the genetic susceptibility is
still important, environmental factors such as obesity or
metabolic disease might be additional contributing factors
to the raised LDL-C level later in life.
The consequence of this elevated LDL-C since birth
leads to the concept of estimating an individual’s “LDL-
C burden,” as is shown in Fig. 1. LDL-C burden is cal-
culated as the sum of an individual’s usual LDL-C multi-
plied by their age. In Fig. 1, the threshold for clinical
CHD is set as the burden achieved by a non-FH subject
at the age of 55 years. An untreated homozygous FH child
reaches this level by the age of 12.5 years and a hetero-
zygous FH adult by the age of 35 years. The cumulative
LDL-C burden by the age of 18 years is 15% lower in FH
patients treated with a low-dose statin from the age of
10 years onwards than in untreated FH patients, and the
clinical threshold will be reached at 53 years. By contrast,
delaying the start of any statin treatment until 18 years
means that the threshold will be reached by 48 years,
suggesting this delay could reduce healthy life expectancy
by 8 years. Other personal characteristics that may influ-
ence age of crossing the potential clinical threshold such
as gender, smoking history, etc. are shown in the box in
Fig. 1. Confirming this view, a meta-analysis involving
312,00 participants showed that long-term exposure to
lower LDL-C at early stages in life was associated with
Table 2 Characteristics and
CIMT measure of patents with
monogenic FH and polygenic
hypercholesterolemia [16•]
Monogenic N = 56 Polygenic N = 30 P value
Patients characteristics
Male N (%) 22 (40) 14 (47) 0.3
Age (years) Mean (SD) 50 (14) 57 (12) 0.03
Total cholesterol (mmol/L) Mean (SD) 8.1 (1.5) 8.2 (1.0) 0.5
LDL-cholesterol (mmol/L) Mean (SD) 5.8 (1.6) 5.9 (0.9) 0.8
HDL-cholesterol (mmol/L) Mean (SD) 1.5 (0.4) 1.9 (1.1) 0.1
Triglycerides (mmol/L) Mean (SD) 1.2 (0.5) 1.6 (0.7) 0.01
On lipid-lowering drug % 75 85 0.7
CIMT measures
Mean cIMT (mm) Mean (SD) 0.74 (0.70–0.79) 0.66 (0.61–0.72) 0.03
Mean bifurcation cIMT (mm) Mean (SD) 0.81 (0.74–0.89) 0.70 (0.62–0.79) 0.05
Mean ICA cIMT (mm) Mean (SD) 0.74 (0.66–0.83) 0.60 (0.52–0.7) 0.04
CIMT carotid intima media thickness, ICA internal carotid artery
Fig. 1 Cumulative LDL-burden,
expressed as mmol/l per year,
over a lifetime in non-FH and FH
individuals with and without
treatment showing threshold for
CHD. (Data from [18])
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a threefold greater reduction in the risk of CHD for each
unit of LDL-C than that observed during treatment with a
statin started later in life. [1••]
Management and Conclusions
The results of the UK Simon Broome Register have shown
that since the introduction of statins, there has been a reduction
in coronary mortality in FH patients by more than a third, and
that in those with no CHD at registration, the CHD rate in
treated FH patients is no greater than in the general population.
Recent analysis of the Register data has confirmed the signif-
icant reduction in fatal CHD in men over the last 20 years, but
with a smaller benefit seen in women, suggesting that women
may not be being treated so often with high intensity statins
[12]. The PCSK9 inhibitors represent a major new contribu-
tion to treatment of severe forms of FH.
Severe hypercholesterolemia needs to be treated inde-
pendently of the genetic defect, due to the undisputable
causal role LDL-C in atherosclerosis. Clearly, all patients
with a clinical diagnosis of FH will need LDL-C levels
reduced significantly, with UK guidelines suggesting by
at least 50% from baseline (https://www.nice.org.uk/
guidance/cg71), and European guidelines to below 2.
5 mmol/l [20]. However, because of the higher LDL-C
burden and in consequence higher atherosclerotic burden
in the monogenic patients, this group needs particularly
intensive LDL-C-lowering, which can best be achieved
under the management of a lipid specialist. For some pa-
tients, to achieve LDL-C target values, may require treat-
ment with multiple agents, and in some may include use
of PCSK9 inhibitors. By contrast, in those who do not
have a monogenic cause for their lipid phenotype, it is
appropriate to estimate their CHD risk using risk algo-
rithms such as QRISK2, and they could be managed in
general practice [6]. The cascade testing recommended in
the families of index cases with a monogenic cause is not
recommended in those with polygenic hypercholesterol-
emia, because the number of “affected” relatives will be
much less than the 50% found in those with a monogenic
cause, and the process will be much less cost-effective.
The use of genetic information to stratify patients with a
clinical diagnosis of FH into those with a monogenic or poly-
genic cause, and to have different management care-path-
ways, is a paradigm example of the utility of genetic in
Precision Medicine. As NGS becomes cheaper, and the bio-
informatics analysis has developed further, this may expand to
whole genome sequencing to give an individual a more com-
plete picture of their future risk of disease. It is also possible
that the large inter-individual variability in the LDL-C re-
sponse to a given dose of statins or PCSK9 inhibitors seen
in different individuals may be caused to some extent by the
genetic differences causing the FH phenotype in monogenic
patients compared to those with polygenic hypercholesterol-
emia. If this could be demonstrated by future research, this
may prove helpful in influencing monitoring and treatment
strategies.
By generating a polygenic SNP score in diagnostic genetic
laboratories, the likelihood of a polygenic etiology in
mutation-negative patients with a clinical diagnosis of FH
can be reported to assist their management. Mendelian ran-
domization and genome-wide association studies have given
significant insights into the role of genetics in dyslipidemia
and cardiovascular risks. This has enabled the creation of ge-
netic risk scores that have demonstrated improved risk predic-
tion when added to clinical markers.
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